WallStSmart
CDTX

Cidara Therapeutics Inc

NASDAQ: CDTX · HEALTHCARE · BIOTECHNOLOGY

$221.38
+0.00% today

Updated 2026-01-07

Market cap
$6.96B
P/E ratio
P/S ratio
4,540.70x
EPS (TTM)
$-11.20
Dividend yield
52W range
$15 – $221
Volume
1.5M

Cidara Therapeutics Inc (CDTX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2012201320142015201620172018201920202021202220232024
Revenue$0.00$0.00$0.00$0.00$0.00$20.91M$12.07M$49.57M$64.29M$23.28M$1.27M
Revenue growth (YoY)-42.3%+310.8%+29.7%-63.8%-94.5%
Cost of revenue$0.00$461000.00$732000.00$42.82M$523000.00$46.40M$68.02M$189000.00$143000.00$36.76M$84.88M
Gross profit$-1.61M$-461000.00$-732000.00$-42.82M$-523000.00$-25.49M$12.07M$49.57M$64.29M$-13.48M$1.27M
Gross margin-121.9%100.0%100.0%100.0%-57.9%100.0%
R&D$12000.00$810000.00$6.71M$23.48M$35.70M$42.82M$49.14M$46.40M$68.02M$73.09M$75.52M$36.76M$156.76M
SG&A$780000.00$272000.00$3.31M$8.84M$12.74M$12.90M$14.14M$16.24M$15.90M$18.74M$18.49M$13.58M$20.61M
Operating income$-792000.00$-1.08M$-11.62M$-32.31M$-48.44M$-55.72M$-63.28M$-41.72M$-71.85M$-42.26M$-29.72M$-27.06M$-176.10M
Operating margin-199.5%-595.4%-85.2%-46.2%-116.2%-13811.9%
EBITDA$-1.08M$-9.84M$-31.85M$-47.70M$-55.05M$-62.76M$-41.40M$-70.80M$-43.48M$-28.49M$-26.95M$-175.87M
EBITDA margin-197.9%-586.7%-87.7%-44.3%-115.7%-13793.6%
EBIT$-792000.00$-1.08M$-10.02M$-32.31M$-48.44M$-55.72M$-63.28M$-41.72M$-71.85M$-42.26M$-29.72M$-27.06M$-176.10M
Interest expense$0.00$0.00$120000.00$271000.00$7000.00$629000.00$221000.00$262000.00$212000.00$191000.00
Income tax$-987000.00$1.70M$-461000.00$-732000.00$-667000.00$4.27M$-1.01M$262000.00$1.44M$272000.00$15000.00
Effective tax rate0.0%42.3%-16.6%1.4%1.5%1.2%-7.8%2.4%-0.4%-3.4%-0.9%-0.1%0.0%
Net income$-792000.00$-1.34M$-11.89M$-32.19M$-48.16M$-55.73M$-59.02M$-41.09M$-72.11M$-43.91M$-29.80M$-22.93M$-169.83M
Net income growth (YoY)-69.7%-785.0%-170.7%-49.6%-15.7%-5.9%+30.4%-75.5%+39.1%+32.1%+23.0%-640.6%
Profit margin-196.5%-597.6%-88.6%-46.4%-98.5%-13319.8%